$ISIS Company News Strong bull trend absorbs

New Post Public Reply Private Reply Replies (0) Message Board

Nov 16, 2014 at 10:26 AM

$ISIS Company News

Strong bull trend absorbs Fed-induced whipsaw 9:59 a.m. Oct. 30, 2014 - Michael Ashbaugh
This tiny biotech company takes the real ice bucket challenge 9:14 a.m. Sept. 2, 2014 - Michael Brush
A lesson in buying low in a high group 11:01 p.m. Sept. 1, 2014 - Michael Kahn
5 companies that will benefit from ALS awareness 6:58 a.m. Aug. 22, 2014 - Jennifer Booton
Investors blow on the dice as Iraq and the Fed shake up markets 8:09 a.m. June 16, 2014 - Shawn Langlois
S&P, Dow pull in from latest record highs 10:10 a.m. June 2, 2014 - Michael Ashbaugh
Health-care-related stocks keep on giving 12:02 p.m. Feb. 12, 2014 - The Trading Deck
See the future 12:42 p.m. Feb. 3, 2014 - Cody Willard
Charting the S&P 500’s excellent 2013 adventure 11:59 a.m. Dec. 23, 2013 - Michael Ashbaugh
Market technicals tame despite debt-ceiling debate 10:43 a.m. Sept. 25, 2013 - Michael Ashbaugh
Isis reaches a new high on tests for treatment of muscular disorder 2:03 p.m. Sept. 19, 2013 - Russ Britt
Isis, Biogen working on ways to fight disease through gene altering 9:59 a.m. Sept. 9, 2013 - Russ Britt
Isis, Novartis, Halozyme all rise on positive product news 10:48 a.m. Sept. 3, 2013 - Russ Britt
Despite positive tests, investors let some air out of Isis Pharmaceuticals 10:30 a.m. July 22, 2013 - Russ Britt
5 stocks to watch 2:35 p.m. July 11, 2013 - The Trading Deck
Onyx share surge lifts several boats in biotech harbor, including ETFs 10:33 a.m. July 1, 2013 - Russ Britt
S&P’s 50-day average marks the technical test 10:39 a.m. June 27, 2013 - Michael Ashbaugh
After the close: Alexion climbs on FDA news, Biogen basks in glory 4:35 p.m. June 26, 2013 - Russ Britt
After dramatic moves, Isis and Allergan dart in different directions 5:18 p.m. June 25, 2013 - Russ Britt
Dissecting the close: Isis soars on data, while Pfizer loses on spin-off 6:26 p.m. June 24, 2013 - Russ Britt

Isis/AstraZeneca Expand Antisense Technology Collaboration - Analyst Blog 4:30 p.m. Nov. 14, 2014 - Zacks.com
Cramer's Lightning Round - VeriFone Is Going To Have A Big Year (11/12/14) 9:05 a.m. Nov. 13, 2014 - Seeking Alpha
'Mad Money' Lightning Round: VeriFone Is Integral to ApplePlay 6:00 a.m. Nov. 13, 2014 - TheStreet.com
Biggest Movers in Healthcare Stocks Now – ARNA ISIS ACAD PBYI 5:45 a.m. Nov. 13, 2014 - InvestorPlace.com
Jim Cramer's 'Mad Money' Recap: Pining for Quiet Stock That Climbs 8:57 p.m. Nov. 12, 2014 - TheStreet.com
Isis Pharmaceuticals (ISIS) Highlighted As Today's Perilous Reversal Stock 9:48 a.m. Nov. 12, 2014 - TheStreet.com
Cramer's Mad Money - The Hottest Stock You've Never Heard Of (11/11/14) 5:20 a.m. Nov. 12, 2014 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Pile Into Housing, Biotech and Pop Cult Names 8:59 p.m. Nov. 11, 2014 - TheStreet.com
One Reason Isis Pharmaceuticals (ISIS) Stock Is Gaining Today 11:24 a.m. Nov. 11, 2014 - TheStreet.com
Isis Pharmaceuticals (ISIS) Is Strong On High Volume Today 10:02 a.m. Nov. 11, 2014 - TheStreet.com
Hottest Healthcare Stocks Now – ICUI ISIS NPSP PDLI 6:30 a.m. Nov. 11, 2014 - InvestorPlace.com
ISIS Pharmaceuticals' (ISIS) CEO Stan Crooke on Q3 2014 Results - Earnings Call Transcript 6:52 p.m. Nov. 7, 2014 - Seeking Alpha
Will Isis Pharmaceuticals (ISIS) Disappoint on Q3 Earnings? - Analyst Blog 6:00 p.m. Nov. 5, 2014 - Zacks.com
Cramer Sees HP Entering Sector as Trouble for 3-D Printing Stocks 11:57 a.m. Nov. 3, 2014 - TheStreet.com
Isis Pharmaceuticals, Inc. (ISIS): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report 8:00 a.m. Oct. 30, 2014 - Zacks.com
Cramer's Lightning Round: Isis Is Still Good (10/29/14) 7:43 a.m. Oct. 30, 2014 - Seeking Alpha
'Mad Money' Lightning Round: Stay Away From Applied Materials 6:00 a.m. Oct. 30, 2014 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Where to Find Bargains Created by the Fed 8:12 p.m. Oct. 29, 2014 - TheStreet.com
Cramer's Lightning Round - Isis Pharmaceuticals Has The Best Pipeline (10/28/14) 6:59 a.m. Oct. 29, 2014 - Seeking Alpha
'Mad Money' Lightning Round: I'm Sticking With Isis Pharmaceuticals 6:00 a.m. Oct. 29, 2014 - TheStreet.com

Isis Pharmaceuticals to Present at Upcoming Investor Conferences 7:00 a.m. Nov. 14, 2014 - PR Newswire - PRF
AstraZeneca and Isis Pharmaceuticals to Co-Develop Targeted Oligonucleotide Delivery Methods 3:01 a.m. Nov. 13, 2014 - PR Newswire - PRF
Critical Alerts For Twitter, Isis Pharmaceuticals, TrueCar and Myriad Genetics Released By InvestorsObserver 9:31 a.m. Nov. 12, 2014 - PR Newswire - PRF
Isis Pharmaceuticals Prices Offering of $425 Million of 1.00% Convertible Senior Notes 7:00 a.m. Nov. 12, 2014 - PR Newswire - PRF
Isis Pharmaceuticals Announces Proposed Offering of $425 Million of Convertible Senior Notes 4:03 p.m. Nov. 10, 2014 - PR Newswire - PRF
Isis Pharmaceuticals Earns $10 Million Milestone Payment From Biogen Idec for Advancement of ISIS-BIIB3 Rx 7:00 a.m. Nov. 6, 2014 - PR Newswire - PRF
Isis Pharmaceuticals Earns $7.5 Million Milestone Payment From AstraZeneca 7:00 a.m. Nov. 5, 2014 - PR Newswire - PRF
Regulus Announces Closing of Public Offering of $103.5M of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 4:05 p.m. Nov. 3, 2014 - PR Newswire - PRF
Isis Pharmaceuticals Earns $5 Million in Milestone Payment From GSK for Advancement of ISIS-GSK5 Rx 7:00 a.m. Nov. 3, 2014 - PR Newswire - PRF
Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 8:40 a.m. Oct. 31, 2014 - PR Newswire - PRF
Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call 7:00 a.m. Oct. 31, 2014 - PR Newswire - PRF
Critical Alerts For AT&T, SolarWinds, Whole Foods Market, FireEye and Isis Pharmaceuticals Released By InvestorsObserver 9:31 a.m. Oct. 30, 2014 - PR Newswire - PRF
Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 7:00 a.m. Oct. 30, 2014 - PR Newswire - PRF
Regulus Announces Pricing of Public Offering of Common Stock 8:10 p.m. Oct. 28, 2014 - PR Newswire - PRF
Isis Pharmaceuticals Earns $18 Million From GSK for Advancing ISIS-TTR Rx 7:00 a.m. Oct. 9, 2014 - PR Newswire - PRF
Critical Alerts For petroleo brasileiro, Herbalife, Micron, FireEye and Isis Pharmaceuticals Released By InvestorsObserver 9:31 a.m. Oct. 7, 2014 - PR Newswire - PRF
Isis Pharmaceuticals to Host Webcast to Discuss ISIS-SMN Rx Results Presented at the World Muscle Society Congress 7:00 a.m. Oct. 2, 2014 - PR Newswire - PRF
Isis Pharmaceuticals Earns $1.5 Million From GSK for the Advancement of ISIS-GSK4 Rx 7:00 a.m. Oct. 1, 2014 - PR Newswire - PRF
Isis Pharmaceuticals to Present at the Leerink Partners Rare Disease Roundtable 7:00 a.m. Sept. 24, 2014 - PR Newswire - PRF
Biotech Stocks in Motion - XOMA, Nanosphere, Isis Pharma, Halozyme Therapeutics, and Synta Pharma 8:45 a.m. Sept. 17, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

D-Wave Quantum Hit with Securities Fraud Lawsuit

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Novo's CagriSema Trials Show Promising Weight Loss

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Championing Change: USTA Mid-Atlantic Gala's Impact

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

EZaccessMD Data Breach: Class Action Lawsuit Looms

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

WHO and RCSI Bahrain Join Forces on Health Initiatives

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

CVS Study: GLP-1 Drugs Effective But Costly

By Hannah Lewis Updated Nov 15, 2026 Category News Views 105

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Portillo's Faces Class Action: Investor Losses at Stake

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...